key: cord-0943168-crrjwtrf
authors: Ritchie, Charles A.; Johnson, Margaret M.; Stowell, Justin T.; Idrees, Hajra; Toskich, Beau; Paz-Fumagalli, Ricardo; Montazeri, Seyed; Fortich, Susana; Franco-Mesa, Camila; Gloviczki, Peter; Bjarnason, Haraldur; Rivera, Candido; Shaikh, Marwan; Moreno-Franco, Pablo; Sanghavi, Devang; Marquez, Christopher P.; McBane, Robert D.; Park, Myung S.; O’Horo, John C.; Meschia, James F.; Erben, Young
title: Resolution of Acute Pulmonary Embolism using anticoagulation therapy alone in Coronavirus Disease 2019
date: 2022-01-25
journal: J Vasc Surg Venous Lymphat Disord
DOI: 10.1016/j.jvsv.2021.12.086
sha: 7ca149be2f203016b1d59c0f93f9187808423c83
doc_id: 943168
cord_uid: crrjwtrf

OBJECTIVE: To investigate the radiographic resolution of acute pulmonary embolism (PE) using contrast enhanced computed tomography (CECT) examinations in patients diagnosed with acute PE while hospitalized with coronavirus 2019 (COVID-19) disease and to understand the mid-term/long-term implications of anticoagulation therapy. METHODS: We identified patients with acute PE per CECT and at least one follow-up CECT from 3/11/2020 to 5/27/2021 using a prospective registry of all hospitalized patients with COVID-19 infection receiving care within a multicenter Health System. Initial and follow-up CECT examinations were reviewed independently by two radiologists to evaluate for PE resolution. The modified Miller score (MMS) was used to assess for thrombus burden at diagnosis and on follow-up. RESULTS: Of the 6070 hospitalized patients with COVID-19 infection, 5.7% (348/6070) were diagnosed with acute PE. 13.5% (47/348) had a follow-up CECT examination. Mean (SD) time to follow-up imaging was 44 (48) days (range: 3-161 days). 72.3% (34/47) of patients had radiographic resolution of PE, with a mean time to follow-up of 48 (43) days (range: 6-239 days). All patients received anticoagulation monotherapy for a mean of 149 (95) days and this included apixaban (63.8%), warfarin (12.8%) and rivaroxaban (8.5%) among others. The mean MMS at PE diagnosis and follow-up was 4.8 (4.2) (range: 1-14) and 1.4 (3.3) (range: 0-16, p<0.0001), respectively. 9 (19%) patients died, at a mean of 13 (8) days after follow-up CECT (range: 1-27 days) and at a mean of 28 (16) days after admission (range: 11-68 days). 78% (7/9) of deaths were associated with progression of COVID-19 pneumonia. CONCLUSION: Hospitalized patients with COVID-19 have a clinically apparent 5.7% rate of developing PE. In patients with follow-up imaging, 72.3% had radiographic thrombus resolution at a mean of 44 days while on anticoagulation. Prospective studies of the natural history of PEs with COVID-19 that include systematic follow-up imaging are warranted to help guide anticoagulation recommendations.

4 radiographic resolution of PE, with a mean time to follow-up of 48 (43) days (range: 6-239 1 days). All patients received anticoagulation monotherapy for a mean of 149 (95) days and this 2 included apixaban (63.8%), warfarin (12.8%) and rivaroxaban (8.5%) among others. The mean 3 MMS at PE diagnosis and follow-up was 4.8 (4.2) (range: 1-14) and 1.4 (3.3) (range: 0- 16, 4 p<0.0001), respectively. 9 (19%) patients died, at a mean of 13 (8) days after follow-up CECT 5 (range: 1-27 days) and at a mean of 28 (16) days after admission (range: 11-68 days). 78% (7/9) 6 of deaths were associated with progression of COVID-19 pneumonia. COVID-19 infection is associated with a procoagulant state leading to increased incidence of 7 venous thromboembolism (VTE). 1,2 Previous reported deep venous thrombosis (DVT) and 8 pulmonary embolism (PE) incidence in patients with COVID-19 ranges from 9% 4 to 26% 5 . The 9 exact pathophysiology of this condition remains unknown, but a theory has been disclosed by 10 McGonagle et al. 3 They proposed that a macrophage activation-like state triggers an extensive 11 "immunothrombosis" in the lung's vessels leading to pulmonary intravascular coagulopathy.

American and European consensus statements on COVID-19 management incorporate 13 guidelines for anticoagulation therapy in patients with COVID-19 associated VTE and are 14 largely based on data for treatment of non-COVID-19 VTE. 6,7 However, the natural history of 15 PE resolution with anticoagulation in the COVID-19 population remains poorly understood. The 16 purpose of this study was to assess the radiographic resolution of PE in hospitalized patients with 17 documented COVID-19 infection and acute PE on contrast enhance chest CT (CECT) and 1 COVID-19 pandemic identified within the three campuses the reporting institutions health 2 system located in Arizona, Florida, Minnesota, and Wisconsin. Using a shared electronic medical 3 record (Epic®; Verona, WI), we identified all patients from 03/11/2020 to 05/27/2021, who 4 tested positive for the SARS-CoV-2 by polymerase chain reaction (PCR) testing or serology.

These dates were selected as the start of standardized polymerase chain reaction (PCR) testing 6 within our institutions, 03/11/2020, and the date of final follow up for patients included within 7 the study, 05/27/2021. From this cohort, any individual hospitalized because of the SARS-CoV-2 8 infection requiring treatment and concurrently diagnosed with an acute PE per CECT was 9 included in this study, a total of 50 patients met these criteria. Manual chart review of 50 10 identified patients was performed to ensure that hospitalization was for treatment of SARS-CoV-11 2 infection as well as how the patient was treated for their PE. Three patients were excluded from 12 the study (1 patient underwent thrombectomy and 2 patients received inferior venocaval filters).

Written informed consent was waived due to the retrospective and anonymized nature of the data 14 collection and reporting. 15 Imaging Protocols and Evaluation 16 There was no standardized imaging protocol for patients with SARS-CoV-2 and for 17 whom there was a suspicion for PE, therefore, CECT obtained for any reason as part of clinical 18 care was included in the study. CECT examinations were included in this study if they meet 19 diagnostic quality by having a Hounsfield Units value of >250 in the lobar pulmonary arteries; 20 this included CT pulmonary angiogram (CTPA) and contrast enhanced CT examinations of the 21 chest. 8 Cross-sectional imaging was performed using 64, 128, 256, Computed Tomography (MDCT). CTPA were performed utilizing a 0.6 mm collimation, 1.5 to 23 J o u r n a l P r e -p r o o f 7 10 mm reconstruction, 12 rotation time being 0.25 to 0.5 seconds, and 3 mm/rotation table speed 1 using a bolus tracking threshold of 100 Hounsfield Units on the pulmonary artery, using up to 2 100 mL of intravenous Omnipaque 300. Contrast enhanced chest CT was performed utilizing a 3 0.6 mm collimation, 1.5 to 10 mm reconstruction, rotation time of 0.5 seconds, and 3 4 mm/rotation table speed using a 40 second delay and 75 mL of intravenous Omnipaque 300. The quick COVID-19 severity index (qCSI) was utilized as a tool to assess disease 5 severity from the infectious stand point to justify ICU care. 12 Scores range from 0 to 12 and there 6 are three categories measured which include respiratory rate (breaths/minute), oxygen saturation 7 (% oxygen saturation measured by pulse oximeter) and amount of oxygen needed to maintain the 8 oxygen saturation measured (L/minute) at the time of evaluation. A score of less than 3 is 9 considered low risk (with an estimated 4% risk); a score between 4-6 is considered low-10 intermediate risk (with an estimated 30% risk), a score between 7-9 is considered high-11 intermediate risk (with an estimated 44% risk) and a score between 10-12 is considered high risk 12 (with an estimated 57% risk) of needing invasive modes of critical illness management such as 13 mechanical ventilation and ICU care. 14 Statistical methods 15 Descriptive data were reported using means and standard deviations for continuous 16 variables or as frequencies for categorical variables. Wilcoxon-Mann-Whitney test and Fisher's 17 exact tests were performed for continuous and categorical parameters. Table I ). The reasons for obtaining a follow-up CECT imaging study were also recorded and 9 included most frequently shortness of breath (29.8%) and follow-up after initial PE diagnosis 10 (25.5%). Comorbidities and reasons for follow-up CECT are shown in Table I . 14.9% (7/47) 11 patients had a history of cancer, and only one patient (2.1%) had a known history of 12 thrombophilia (heterozygous for factor V Leiden). Forty-two percent (20/47) of patients required 13 intensive care unit (ICU) care; their ICU length of stay and length of hospitalization was 7±14 14 and 14±19 days, respectively. The D-dimer on the day of PE diagnosis was 15 14971.2±14697.9mg/mL fibrinogen equivalent units (FEU). All patients were anticoagulated on 16 the day of PE diagnosis and were discharged most often on apixaban (63.8%) with a plan for at 17 least three months anticoagulation (149±95 days) (Table II) 4.3%; p=0.12). However, the qCSI was different among groups who required ICU care versus 5 those who did not (mean qCSI, 5.9 (3.7) vs. 2.5 (3.4); p=0.0021); which correlates with the 6 infectious disease burden in those individuals with already a PE diagnosis (Table IIIa) . 7 Comparison between the cohort with follow-up CECT and the entire pulmonary embolism (PE) 8 group 9

Within the initial cohort diagnosed with PE, 33.9% required ICU care as opposed to 10 42.6% of the follow-up CECT cohort (p=0.41). In addition, the number of deaths within each 11 cohort was also similar (13.3% vs 12.8%, p=1.00). Lastly, the number of patients affected with 12 deep venous thrombosis in each cohort was again similar (17.9% vs 21.3%, p=0.55) ( Table   13 IIIb).

This study identified 47 patients with pulmonary embolism in a cohort of hospitalized COVID-19 is associated with a hypercoagulable state 15 with active inflammatory 7 cytokines which seem to contribute to mortality in critically ill patients. 16 Both "fibrinolytic patients. The ability to differentiate the mechanism of PE may be useful for guiding therapy. 20 Furthermore, the optimal type and duration of anticoagulation therapy for patients with COVID-21 19 associated PE has yet to be investigated in randomized controlled trials. Reason to obtain repeat cross-sectional imaging n (%) Shortness of breath 14 (29.8) Follow-up after initial pulmonary embolism diagnosis 12 (25.5) New oxygen requirement 5 (10.6) Rising D-dimer 5 (10.6) Chest pain 3 (6.4) Re-evaluation due to enlarged lymph nodes, unwitnessed fall, elevated white blood cell count, cancer assessment, refractory hypoxemia, evaluation of pulmonary infiltrate, spontaneous pneumothorax 8 (17.0) J o u r n a l P r e -p r o o f . Axial cuts of a computed tomography angiography on a hospitalized patient with COVID-19 infection demonstrating: A) presence of pulmonary embolism (blue arrow) and B) resolution of pulmonary embolism (blue arrow) on follow-up imaging 21 days later after the initiation of anticoagulation therapy; C) lung window demonstrating degree of parenchymal disease due to COVID-19 infection (blue circle) and D) improvement of parenchymal disease on follow-up imaging (blue circle) (CECT) imaging and those patients within the initial pulmonary embolism cohort 16 

Incidence of acute 7 pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis

Pulmonary embolism 10 in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review

Pulmonary 13 intravascular coagulopathy in COVID-19 pneumonia -Authors' reply

Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019-17 positive patients predicted for higher mortality and prolonged intensive care unit and hospital 18 stays in a multisite healthcare system

Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute 9 pulmonary embolism

Association of hypercoagulation with 11 severe acute respiratory syndrome coronavirus 2 infection

A 14 Review of Pathophysiology, Clinical Features, and Management Options

COVID-19, Antiphospholipid Antibodies, 18 and Catastrophic Antiphospholipid Syndrome: A Possible Association

Evaluation of